# Sequential Regimen of Bendamustin-Debulking Followed by Obinutuzumab, Acalabrutinib and Venetoclax in Patients With Relapsed/Refractory CLL

> **NCT03787264** · PHASE2 · COMPLETED · sponsor: **German CLL Study Group** · enrollment: 46 (actual)

## Conditions studied

- Chronic Lymphoid Leukemia

## Interventions

- **DRUG:** Bendamustine
- **BIOLOGICAL:** Obinutuzumab
- **BIOLOGICAL:** Acalabrutinib
- **BIOLOGICAL:** Venetoclax

## Key facts

- **NCT ID:** NCT03787264
- **Lead sponsor:** German CLL Study Group
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-01-14
- **Primary completion:** 2021-02-11
- **Final completion:** 2023-09-26
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2024-12-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03787264

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03787264, "Sequential Regimen of Bendamustin-Debulking Followed by Obinutuzumab, Acalabrutinib and Venetoclax in Patients With Relapsed/Refractory CLL". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03787264. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*